New mRNA-LNP Vaccine Spurs Multi-Functional Immune Response

Compuscript Ltd

https://doi.org/10.1016/j.apsb.2025.10.006

This new article publication from Acta Pharmaceutica Sinica B, discusses how an innovative and stable mRNA-LNP microneedle vaccine elicits humoral and multifunctional cellular immune responses.

During the COVID-19 pandemic, the use of lipid nanoparticles (LNPs) augmented the development of mRNA vaccines. However, their ultralow-temperature storage and transportation requirements, as well as their heavy reliance on injection by professional medical staff, have limited large-scale vaccination in many developing countries. The authors of this article developed a simple and widely deployable microneedle (MN) vaccine delivery system (mLNP-man-MN) for mannose-modified LNPs (mLNP-man) loaded with mRNA encoding the SARS-CoV-2 spike receptor-binding domain by utilizing three-dimensional printing and polydimethylsiloxane micro molding methods. This delivery system is composed of a dissolvable polymer mixture that was optimized for high bioactivity by screening formulations in vitro. It was demonstrated that this MN system can maintain the physicochemical properties and bioactivity of the mRNA-LNP complex even when stored at 4 °C for at least one month or at 25 °C for two weeks. Moreover, mLNP-man-MNs target the epidermis and dermis, which are rich in antigen-presenting cells, thereby eliciting effective innate immune responses and inducing robust systemic humoral responses, as well as multifunctional cellular immunity in the spleen. Importantly, the MN system induced a certain level of pulmonary T-cell responses compared to those induced by intramuscular injections, thereby providing some protection against lung invasion by the SARS-CoV-2 pseudovirus in mice.

Keywords: Microneedle, mRNA, Lipid nanoparticles, Mannose, Stability, Antigen-presenting cells, Systemic humoral, Cellularc immunity

Graphical Abstract: available at https://ars.els-cdn.com/content/image/1-s2.0-S2211383525006793-ga1_lrg.jpg

A simple and widely deployable microneedle (MN) vaccine delivery system (mLNP-man-MN) was developed for mannose-modified LNPs (mLNP-man) loaded with mRNA encoding the SARS-CoV-2 spike receptor-binding domain by utilizing three-dimensional printing and polydimethylsiloxane micro molding methods.

/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.